Optimi Health prices an oversubscribed US$15 million public offering and advances a Nasdaq uplisting to support growth in psychedelic pharmaceutical manufacturing

Optimi Health has priced an oversubscribed US$15 million public offering tied to a planned Nasdaq uplisting, signaling investor demand and a push to expand its position in psychedelic pharmaceutical manufacturing. The financing centers on capital markets activity rather than a specific drug program, with the uplisting aimed at increasing visibility, liquidity, and access to a broader investor base. The move is relevant because Optimi operates in the legal psychedelic supply and manufacturing space, where public financing can support production scale-up, regulatory work, commercial partnerships, and broader corporate growth. A Nasdaq listing can also strengthen credibility with institutional investors and place psychedelic-health companies more firmly inside mainstream biotech and public-market infrastructure.